Semantic Scholar uses AI to extract papers important to this topic.
Enzalutamide, an androgen-receptor inhibitor, has been associated with improved overall survival in men with… Expand BACKGROUND Men with nonmetastatic, castration‐resistant prostate cancer and a rapidly rising prostate‐specific antigen (PSA… Expand BACKGROUND
Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant… Expand BACKGROUND
The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of… Expand BACKGROUND
Abiraterone, an androgen synthesis inhibitor, has been successfully used in the treatment of castration-resistant… Expand Persistent androgen receptor (AR) transcriptional activity underlies resistance to AR-targeted therapy and progression to lethal… Expand UNLABELLED
Despite the impressive clinical activity of the second-generation antiandrogens enzalutamide and ARN-509 in patients… Expand UNLABELLED
Castration-resistant prostate cancer (CRPC) is the most aggressive, incurable form of prostate cancer. MDV3100… Expand IntroductionThe androgen receptor (AR) is widely expressed in breast cancers and has been proposed as a therapeutic target in… Expand BACKGROUND
Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major… Expand